Zygolide gives equine vets a new FDA-approved pergolide option
Zygolide gives equine vets a new FDA-approved pergolide option
Dechra said in January 2026 that the FDA approved Zygolide, a 1 mg pergolide tablet for horses with pituitary pars intermedia dysfunction, or PPID, also called equine Cushing’s disease. The company is positioning it as the first FDA-approved bioequivalent generic to Prascend, with features aimed at day-to-day administration, including peppermint flavoring and a 360-degree, half-scored tablet to support more precise dose adjustments. Labeling says it’s indicated to control clinical signs of PPID in horses, with a starting dose of 2 mcg/kg once daily and a maximum labeled dose of 4 mcg/kg daily. In promotional placements in The Horse, Dechra also leaned into owner-facing messaging around helping horses “feel their best,” “rediscover[ing] the partnership,” and offering “cost-effective treatment,” underscoring that the launch is being framed around both quality of life and affordability. (dechra-us.com)
Why it matters: For veterinary professionals, the significance is less about a new mechanism and more about access, adherence, and cost. PPID is a chronic disease that often requires lifelong daily pergolide plus repeat endocrine monitoring, and nearly 42% of horses in the pivotal field study needed a dose increase by day 90. A lower-cost FDA-approved generic could help some pet parents stay on therapy, especially in horses needing higher doses, while the scored tablet design may make titration easier in practice. Dechra’s advertising has explicitly highlighted cost-effectiveness, including a pricing claim tied to Valley Vet in March 2026, which reinforces affordability as a central part of the rollout. At the same time, vets will still need to counsel clients on known pergolide adverse effects, especially transient inappetence, lethargy, weight loss, and behavioral changes. (dechra-us.com)
What to watch: Watch for how quickly Zygolide gains distribution through equine practices and online pharmacies, and whether pricing meaningfully shifts long-term PPID treatment decisions in the months ahead. The early owner-directed campaign suggests Dechra is trying to drive recognition as well as prescribing, so uptake may depend not just on clinic stocking but on whether the product’s quality-of-life and cost messaging resonates with horse owners managing chronic PPID. (dechra-us.com)